Paradigm, Forma Therapeutics Partner to ID Molecular Markers for Preclinical Candidates | GenomeWeb

NEW YORK (GenomeWeb) – Paradigm and Forma Therapeutics today announced a multiyear partnership to identify predictive response biomarkers and measure pharmacodynamic activity for two of Forma's advanced preclinical candidates.

Paradigm will use its technology to evaluate the potential of molecular markers to predict clinical outcomes, which would enable Forma "to efficiently match our drugs with high-quality molecular assays to realize a personalized approach to cancer drug development," Forma President and CEO Steven Tregay said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.